EP0097630B1 - New thrombin inhibiting compounds - Google Patents

New thrombin inhibiting compounds Download PDF

Info

Publication number
EP0097630B1
EP0097630B1 EP83850149A EP83850149A EP0097630B1 EP 0097630 B1 EP0097630 B1 EP 0097630B1 EP 83850149 A EP83850149 A EP 83850149A EP 83850149 A EP83850149 A EP 83850149A EP 0097630 B1 EP0097630 B1 EP 0097630B1
Authority
EP
European Patent Office
Prior art keywords
compound
thrombin
naphthyl
formula
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP83850149A
Other languages
German (de)
French (fr)
Other versions
EP0097630A3 (en
EP0097630A2 (en
Inventor
Carl Göran Claeson
Stig Ingemar Gustavsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Priority to AT83850149T priority Critical patent/ATE22882T1/en
Publication of EP0097630A2 publication Critical patent/EP0097630A2/en
Publication of EP0097630A3 publication Critical patent/EP0097630A3/en
Application granted granted Critical
Publication of EP0097630B1 publication Critical patent/EP0097630B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Definitions

  • Thrombin plays an important role in the coagulation process, where is as last enzyme, in the coagulation cascade, tranfers fibrinogen to polymerizable fibrin. This is done by splitting of Arg-bonds. Thrombin has just close to its active center a "specificity pocket" with great affinity for the positively charged guanidino group in Arg. This knowledge has been used for construction of synthetic substrates and inhibitors of thrombin. Since a long time it is known that substituted Arg esters can be split by thrombin, e.g. Bz-Arg-OEt (BAEE) and Tos-Arg-OMe (TAME). The last-named ester acts, by being a competitive substrate, also as inhibitor to the reaction ofthrombin with fibrinogen. The plasma coagulation time is prolonged e.g. by addition of TAME.
  • BAEE Bz-Arg-OEt
  • TAME Tos-Arg-OMe
  • a better thrombin inhibitor can be obtained by making the Arg-bond not cleavable.
  • Okamoto et al. (1,2) has described thrombin inhibitors, where the carboxylic group of Arg is bound to sec. amines: FR-A-2 290 192 discloses compounds of the formula II with thrombin inhibitor activity.
  • Markwardt (3,4) has modified the structure II by inserting the synthetic amino acid p-amidino- phenylalanine (Aph), an anlog to Arg, instead of Arg.
  • the compounds (III) thereby obtained seem to be about as good thrombin inhibitors as the corresponding compounds (II) made by Okamoto.
  • Another arginine analog, p-guanidinophenylalanine (GpH) was first synthesized by Elliot (5) .
  • Klausner (6) synthesized the derivative Tos-Gph-OMe, which appeared to be a goods substrate for trypsin, but on the other hand a bad substrate for thrombin but with ability to inhibit the amidase- and esterase activity of thrombin.
  • Tsunematso (7) has synthesized by Bz-GpH-OEt too and has found that it as substrate for trysin is comparable with Tos-Gph-OMe and Tos-Arg-OMe (TAME).
  • the new compounds (I) according to the invention have very good thrombin- inhibiting properties which to advantage can be compared with the corresponding Arg- as well as Aph-derivatives (II and III).
  • Table 2 gives Ki (thrombin) for the corresponding Gph- and Aph-derivatves. Also in this comparison the Gph-derivatives show a distinct advantage.
  • the new prepared compounds according to the invention have a very specific thrombin inhibiting effect.
  • factor Xa is inhibited up to 1000 times less than thrombin.
  • the compounds are therefor very useful as selective inhibitors for thrombin when determining factor Xa in a medium (e.g. blood), where thrombin may be present and disturb the determination of factor Xa.
  • a medium e.g. blood
  • thrombin may be present and disturb the determination of factor Xa.
  • the new aryl-sulfonyl-L-p-guanidinophenylalanine amides and the pharmaceutically acceptable acid addition salts thereof according to the invention can in their capacity as good thrombin inhibitors also be used as anticoagulants in therapy and prophylax of thrombosis.
  • the starting material according to a) above can be obtained by removal of the protecting group Z from a compound of the formula by reaction with e.g. trifluoroacetic acid, wherein R 1 and R 2 are as defined previously and Z is a removable group as -COOR°, wherein R° is a hydrocarbon residue e.g. alkyl.
  • the starting material according to b) above can be obtained by e.g. a reaction between a compound of the formula and a compound of formula wherein Z, R, and R 2 are as defined previously, to formation of a compound of the formula which protecting group Z thereafter is removed to formation of a compound which thereafter by reaction with a compound of the formula wherein R 1 , R 2 , Y and Z are as defined previously, is transferred to the starting material according to b).
  • the new compounds according to the invention show a asymmetric center * ) and appear therefore in two stereoisomeric forms as well as in form of racemate.
  • the two optical antipodes can be separated with help of known methods and the invention includes the racemate as well as these antipodes separately as free base as well as salt. Specially preferred is the L-form.
  • the product can be obtained as pharmaceutically acceptable acid addition salts by reacting one of the free bases with an acid, such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, citric, maleic, succinic, lactic, tartaric, gluconic, benzoic, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic acid or the like.
  • an acid such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, citric, maleic, succinic, lactic, tartaric, gluconic, benzoic, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic acid or the like.
  • an acid such as hydrochloric, hydrobromic, hydroiodic, ni
  • the residue is dissolved in methanol and chromatographed on a Sephadex R LH20 column in methanol with methanol as medium for eluation.
  • the fraction containing the compund 1a is evaporated to dryness in vacuum, the product is obtained as an amorphous powder.
  • 1,1 g of 4-methylpiperidide in 20 ml of DMF is acidified with 1 ml of conc. HCI and is then evaporated to dryness in vacuum.
  • the residue together with 3,2 g of BOC-p-guanidino-Phe-OH [Klausner Y. S. et al. Biochem. J. 169, 157-67 (1978)] and 1,35 g of HOBT are dissolved in 20 ml DMF.
  • 2 g of DCCI is added.
  • the reaction mixture is stirred for 2 hours at a low temperature and then at room temperature over night.
  • the prepared DCU is filtered off and the reaction mixture is evaporated in vacuum to an oil.
  • the oil is dissolved in 80 ml of n-butanol.
  • the butanol solution is washed in sequence with 10% NaCI in water, 0,5 M NaHC0 3 in 5% NaCI in water and 10% NaCI in water.
  • the butanol phase is dried over Na 2 S0 4 and evaporated in vacuum.
  • Chromatography on Sephadex R LH20 in methanol and an QAE Sephadex R A50 in chloride form in ethanol-water (1:1) gives after lyophilizing from water a pure compound 2a.
  • 1,3 g of compound 2a is deprotected with 30 ml of 25% TFA in dichloromethane according to 1b.
  • the TFA salt of H-p-guanidino-Phe-4-methyl-piperidide is dissolved in 25 ml of DMF and after cooling 0,42 mg of Et 3 N is added to give a weak basic reaction.
  • First 3,3 g of naphthalene-2-sulfonylchloride and then 0,45 ml of Et 3 N are added to the solution.
  • the reaction mixture is stirred for 1 hour at a lowtemperature and for 1 hour at room temperature.
  • Et 3 N hydrochloride is filtered off and the DMF-solution is evaporated in vacuum. Chromatography and lyophilizing according to ex. 1 gives a pure compound 2.
  • the inhibition of reaction of the enzymes (human thrombin; Sigma Chemical Co., St. Louis, USA and human factor Xa; KabiVitrum AB, Sweden) with the substrates (S-2238 resp. S-2222, Kabi Diagnostica, Swiss) was determined at three different substrate concentrations from 0,3 to 2 Km. Six different inhibitor concentrations, which give inhibition from 40% to 90%, were incubated with the enzyme for 30 seconds at 37°C.
  • the buffer composition, ionic strength, pH and enzyme concentration were the same as those recommended in the booklets from Kabi Diagnostica.
  • the initial reaction velocity (AA/min) was measured on a recorder at 405 nm. Ki values were then graphically determined from Dixon and Lineweaver-Burk diagrams.
  • a volume of 200 ⁇ l citrate-plasma was heated for 1 minute at 37°C.
  • the coagulation was started by adding 10 ⁇ l fresh thrombin solution (about 5 NIH U/ml) and the coagulation time was registrated by a fibrinometer.
  • the plasma was incubated for 30 seconds with 10 ⁇ l inhibitor solution at different concentrations before the thrombin solution was added.
  • Thrombin time designates the concentration (mol/I) of the inhibitor, which doubles the thrombin time of dog plasma.
  • the Arg derivatives have been synthesized according to ref. 1 and 2.
  • Tos-Gph-OMe has been synthesized according to ref. 6. Thrombin inhibition constants of Aph- and Gph-derivatives
  • Ki of thrombin is given in mol/I

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

New thrombin inhibiting N<sup>α</sup>-arylsulfonyl-p-guanidinophenylalanine amides of the formulawherein Ar is a substituted aryl and R, and R<sub>2</sub> are an alkyl group having 1-5 carbon atoms or together with the amine nitrogen form an heterocyclic ring, in racemate form as well as in form of optical active antipodes, theirs pharmaceutically acceptable salts, methods for their preparation, pharmaceutical composition and diagnostical preparation containing these compunds, use of the compounds in treatment of thrombosis and methods of treatment of thrombosis as well as methods for determination of thrombin concentration in blood.

Description

    Technical Field
  • The present invention is related to new thrombin inhibiting Na-arylsulfonyl-p-guandinophenylalanine amides of the general formula:
    Figure imgb0001
    wherein Ar is o-, m- or p-tolyl, naphthyl-1, naphthyl-2 or 5-dimethylamino-1-naphthyl and R, and R2 is an alkyl group having 1-5 carbon atoms or
    Figure imgb0002
    wherein n=2 or 3 and X is a single bond, CH2, CH-CH3, CH-C2H5, CH-C3H7, 0, NH or N-CH3.
    • Background Art
  • Thrombin plays an important role in the coagulation process, where is as last enzyme, in the coagulation cascade, tranfers fibrinogen to polymerizable fibrin. This is done by splitting of Arg-bonds. Thrombin has just close to its active center a "specificity pocket" with great affinity for the positively charged guanidino group in Arg. This knowledge has been used for construction of synthetic substrates and inhibitors of thrombin. Since a long time it is known that substituted Arg esters can be split by thrombin, e.g. Bz-Arg-OEt (BAEE) and Tos-Arg-OMe (TAME). The last-named ester acts, by being a competitive substrate, also as inhibitor to the reaction ofthrombin with fibrinogen. The plasma coagulation time is prolonged e.g. by addition of TAME.
  • A better thrombin inhibitor can be obtained by making the Arg-bond not cleavable. Okamoto et al.(1,2) has described thrombin inhibitors, where the carboxylic group of Arg is bound to sec. amines:
    Figure imgb0003
     FR-A-2 290 192 discloses compounds of the formula II with thrombin inhibitor activity.
  • US 3 978 045 describes compounds of the formula II, wherein Ar-S02 is a dansyl group. These compounds are indicated to have antithrombotic activity.
  • Markwardt(3,4) has modified the structure II by inserting the synthetic amino acid p-amidino- phenylalanine (Aph), an anlog to Arg, instead of Arg. The compounds (III) thereby obtained seem to be about as good thrombin inhibitors as the corresponding compounds (II) made by Okamoto.
    Figure imgb0004
    Another arginine analog, p-guanidinophenylalanine (GpH), was first synthesized by Elliot(5). Klausner(6) synthesized the derivative Tos-Gph-OMe, which appeared to be a goods substrate for trypsin, but on the other hand a bad substrate for thrombin but with ability to inhibit the amidase- and esterase activity of thrombin.
  • Tsunematso(7) has synthesized by Bz-GpH-OEt too and has found that it as substrate for trysin is comparable with Tos-Gph-OMe and Tos-Arg-OMe (TAME).
    • Description of the Invention
  • Now we have found that the new compounds (I) according to the invention have very good thrombin- inhibiting properties which to advantage can be compared with the corresponding Arg- as well as Aph-derivatives (II and III). Table 1 compares Gph- and Arg=derivatives wiuth with respect to the inhibition constant (Ki) for thrombin and prolongation of coagulation time initiated by thrombin (thrombin time). Especially the thrombin times show the advantages of the Gph-derivatives. Table 2 gives Ki (thrombin) for the corresponding Gph- and Aph-derivatves. Also in this comparison the Gph-derivatives show a distinct advantage.
  • The new prepared compounds according to the invention have a very specific thrombin inhibiting effect. E.g. factor Xa is inhibited up to 1000 times less than thrombin. The compounds are therefor very useful as selective inhibitors for thrombin when determining factor Xa in a medium (e.g. blood), where thrombin may be present and disturb the determination of factor Xa. Besides this diagnostic use of the new compounds as thrombin inhibitors they are also useful for a direct specific determination of thrombin in' blood.
  • The new aryl-sulfonyl-L-p-guanidinophenylalanine amides and the pharmaceutically acceptable acid addition salts thereof according to the invention can in their capacity as good thrombin inhibitors also be used as anticoagulants in therapy and prophylax of thrombosis.
  • In the synthesis of the new thrombin inhibitors, protecting groups and coupling methods traditionally well-known in chemistry can be used. The C-terminal amide residues are also coupled using methods of synthesis which are well-known in the organic chemistry. Purifying of intermediates and end products is made by precipitation, crystallization or gel filtration chromatography.
  • Thus the compounds according to the invention can be prepared by
  • a) reaction between a compound of the formula
    Figure imgb0005
    wherein R, and R2 are as defined previously, and a compound of the formula
    Figure imgb0006
     wherein Y is a reactive group, e.g. halogen as CI which together with H2N can form a sulfonamide group and where Ar is as defined previously.
  • b) by removal of the N02-group e.g. by hydrogenation in a compound of the formula
    Figure imgb0007
    wherein R1, R2 and Ar are as defined previously.
  • The starting material according to a) above can be obtained by removal of the protecting group Z from a compound of the formula
    Figure imgb0008
    by reaction with e.g. trifluoroacetic acid, wherein R1 and R2 are as defined previously and Z is a removable group as -COOR°, wherein R° is a hydrocarbon residue e.g. alkyl.
  • The starting material according to b) above can be obtained by e.g. a reaction between a compound of the formula
    Figure imgb0009
     and a compound of formula
    Figure imgb0010
    wherein Z, R, and R2 are as defined previously, to formation of a compound of the formula
    Figure imgb0011
    which protecting group Z thereafter is removed to formation of a compound
    Figure imgb0012
    which thereafter by reaction with a compound of the formula
    Figure imgb0013
    wherein R1, R2, Y and Z are as defined previously, is transferred to the starting material according to b).
  • The new compounds according to the invention show a asymmetric center *) and appear therefore in two stereoisomeric forms as well as in form of racemate. The two optical antipodes can be separated with help of known methods and the invention includes the racemate as well as these antipodes separately as free base as well as salt. Specially preferred is the L-form.
  • Many different organic and inorganic acids can be employed to form acid addition salts of the new N°- arylsulfonyl-p-guanidinophenylalanine amides of this invention. The product of the reactions described above can be isolated in free form or as acid addition salts. In addition, the product can be obtained as pharmaceutically acceptable acid addition salts by reacting one of the free bases with an acid, such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, citric, maleic, succinic, lactic, tartaric, gluconic, benzoic, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic acid or the like. Similarly, a treatment of the acid addition salts by reaction of a base gives as result a reformation of the free amide or ester.
  • The invention is described from the following not limiting examples. Abbreviations
    • Arg = L-Arginine
    • Phe = L-Phenylalanine
    • Aph = p-Amidino-Phe
    • Gph = p-Guanidino-L-Phe
    • Dansyl = 5-Dimethylamino-1-naphthalenesulfonyl
    • Bz = Benzoyl
    • Et = Ethyl
    • Me = Methyl
    • BOC = t-Butyloxycarbonyl
    • Ac = Acetyl
    • DCCI = Dicyclohexylcarbodiimide
    • DCU = Dicyclohexylurea
    • DMF = Dimethylformamide
    • HOBT = N-Hydroxybenzotriazole
    • TFA = Trifluoroacetic acid
    • TLC = Thin Layer Chromatography

    Used Methods for Thin Layer Chromatography
  • At TLC-analysis pre-fabricated glass plates, with silica gel F254 (Merck) as an absorption medium, are used. The solvent systems used are (volume ratios):
    • A: n-Butanol: AcOH: H20 (3:2:1)
    • Pas: Chloroform: MeOH: AcOH: H20 (34:4:9:2)
    • Following chromatography, the plate is inspected in UV light (254 mm) and then developed with chlorine/o-tuluidin reagent according to normal procedure. The given R, values are the result of single experiments.
    Example 1 NI-Dansyl-p-guanidino-Phe-piperidide hydrochloride 1 a BOC-p-(nitroguanidino)-Phe-piperidide
  • 1.3 g of BOC-p-(nitroguanidino)-Phe-OH (Moore S. et al. J. Chem. Soc. Perkin I 1977, 2025―30) in 15 ml of DMF is cooled to -15°C. 0.5 ml of Et3N and 0.5 ml of isobutylchloroformiate is added with stirring. After 15 min. 0.4 ml of piperidine is added and the solution is stirred at continued cooling for 1 hour and then further 1 hour at room temperature. The reaction mixture is evaporated in vacuum to an oil which is triturated with water and dried. The residue is dissolved in methanol and chromatographed on a SephadexR LH20 column in methanol with methanol as medium for eluation. The fraction containing the compund 1a is evaporated to dryness in vacuum, the product is obtained as an amorphous powder.
  • Yield: 0.95 g (62%) of compound 1a a
  • TLC: R, = 0.79 (Pas)
    • 1 b N°-Dansyl p-(nitroguanidino)Phe-piperidide
  • 1,5 g of 1a is suspended in a 25% solution of TFA in dichloromethane and is stirred at room temperature for 30 min. Dichloromethane is evaporated. The residue is cooled on an ice-bath and ca 1000 ml dry ether is added under vigorous stirring. The precipitate formed is filtered and washed with dry ether and dried in vacuum over NaOH. The obtained TFA salt of H-p-(nitroguanidino)-Phe-piperidide is dissolved in 20 ml tetrahydrofurane-water (9:1) and neutralized at a low temperature (about -10°C) of 0.55 ml of ET3N. 1.2 g of dansylchloride and further 0.6 ml of Et3N is added. The solution is stirred for 2 hours at a low temperature and then at room temperature over night. The precipitated product is filtered and washed carefully with water and thereafter with ether.
  • Yield: 1.8 g (92%) of compound 1b.
  • TLC: Rf = 0.84 (Pa6)
    • 1. N°-Dansylp-guanidino-Phe-piperidide hydrochloride
  • 200 mg of Ibis suspended in 10 ml of methanol and 0,07 ml of con. HCI and 20 mg palladium on carbon (10%) are added. The solution is hydrogenated at room temperature and at atmospheric pressure is hydrogenated at room temperature and at atmospheric pressure for 48 h. The catalyst is filtered off and the reaction mixture is evaporated. The residue is dissolved in 5 ml of methanol and chromatographed on SephadexR LH20 in methanol with methanol as medium for eluation. The fraction containing compound 1 is evaporated. The residue is dissolved in 5 ml of ethanol:water (1:1) and is ion exchanged on QAE SephadexR A25 in chloride form in ethanol:water (1:1) with the same medium for eluation. The fraction containing the pure compound 1 is evaporated and the residue is lyophilized from water.
  • Yield: 150 mg (71%) of compound 1
  • TLC: Rf = 0,43 (A) shows one spot.
  • Data of analysis vide table 3.
    • Example 2 Na-(Naphthalene-2-sulfonyl)-p-guanidino-Phe-4-methyl-piperidide hydrochloride 2a BOC-p-guanidino-Phe-4-methyl-piperidine hydrochloride
  • 1,1 g of 4-methylpiperidide in 20 ml of DMF is acidified with 1 ml of conc. HCI and is then evaporated to dryness in vacuum. The residue together with 3,2 g of BOC-p-guanidino-Phe-OH [Klausner Y. S. et al. Biochem. J. 169, 157-67 (1978)] and 1,35 g of HOBT are dissolved in 20 ml DMF. After cooling in an ice bath 2,5 g of DCCI is added. The reaction mixture is stirred for 2 hours at a low temperature and then at room temperature over night. The prepared DCU is filtered off and the reaction mixture is evaporated in vacuum to an oil. The oil is dissolved in 80 ml of n-butanol. The butanol solution is washed in sequence with 10% NaCI in water, 0,5 M NaHC03 in 5% NaCI in water and 10% NaCI in water. The butanol phase is dried over Na2S04 and evaporated in vacuum. Chromatography on SephadexR LH20 in methanol and an QAE SephadexR A50 in chloride form in ethanol-water (1:1) gives after lyophilizing from water a pure compound 2a.
  • Yield: 3,0 g (68%) of compound 2a
  • TLC: R, = 0,64 (Pas)
    • 2. Na-(Naphthalene-2-sulfonyl)-p-guanidino-Phe-4-methyl-piperidide hydrochloride
  • 1,3 g of compound 2a is deprotected with 30 ml of 25% TFA in dichloromethane according to 1b. The TFA salt of H-p-guanidino-Phe-4-methyl-piperidide is dissolved in 25 ml of DMF and after cooling 0,42 mg of Et3N is added to give a weak basic reaction. First 3,3 g of naphthalene-2-sulfonylchloride and then 0,45 ml of Et3N are added to the solution. The reaction mixture is stirred for 1 hour at a lowtemperature and for 1 hour at room temperature. After cooling Et3N hydrochloride is filtered off and the DMF-solution is evaporated in vacuum. Chromatography and lyophilizing according to ex. 1 gives a pure compound 2.
  • Yield: 1,24 g (79%) of compound 2
  • TLC: Rf = 0,51 (A) shows one spot
  • Data of analysis vide table 3.
    • Determination of thrombin inhibition
  • Data and test results of other synthesized aryl-p-guanidinophenylalanine amides are compared in table 3, where compound V is prepared according to ex. 1 and the other compounds are prepared according to ex. 2.
    • Determination of Ki
  • The inhibition of reaction of the enzymes (human thrombin; Sigma Chemical Co., St. Louis, USA and human factor Xa; KabiVitrum AB, Stockholm) with the substrates (S-2238 resp. S-2222, Kabi Diagnostica, Stockholm) was determined at three different substrate concentrations from 0,3 to 2 Km. Six different inhibitor concentrations, which give inhibition from 40% to 90%, were incubated with the enzyme for 30 seconds at 37°C. The buffer composition, ionic strength, pH and enzyme concentration were the same as those recommended in the booklets from Kabi Diagnostica. The initial reaction velocity (AA/min) was measured on a recorder at 405 nm. Ki values were then graphically determined from Dixon and Lineweaver-Burk diagrams.
    • Thrombin Time
  • A volume of 200 µl citrate-plasma was heated for 1 minute at 37°C. The coagulation was started by adding 10 µl fresh thrombin solution (about 5 NIH U/ml) and the coagulation time was registrated by a fibrinometer. At the inhibitor experiments the plasma was incubated for 30 seconds with 10 µl inhibitor solution at different concentrations before the thrombin solution was added.
    Figure imgb0014
     Thrombin inhibition by Arg- and Gph-derivatives
  • Ki of thrombin in mol/I
  • "Thrombin time" designates the concentration (mol/I) of the inhibitor, which doubles the thrombin time of dog plasma.
  • The Arg derivatives have been synthesized according to ref. 1 and 2.
  • Tos-Gph-OMe has been synthesized according to ref. 6.
    Figure imgb0015
    Thrombin inhibition constants of Aph- and Gph-derivatives
  • Ki of thrombin is given in mol/I
  • Ki-values of Aph-derivatives are taken from ref. 3
  • They refer to the racemates of the compounds and are determined by bovine thrombin and DL- benzoylarginine-p-nitroanilide.
    Figure imgb0016
    Figure imgb0017
    Figure imgb0018
    Figure imgb0019

Claims (14)

1. Na-arylsulfonyl-p-guanidinophenylalaline amides of the formula
Figure imgb0020
wherein Ar is ortho-, meta- or para-tolyl, naphthyl-1, naphthyl-2 or 5-dimethylamino-1-naphthyl; R, and R2 are an alkyl group having 1-5 carbon atoms or
Figure imgb0021
wherein n=2 or 3 and X is a single bond, CH2, CH-CH3, CH-C2H5, CH-C3H7, 0, NH or N-CH3, in free base form or in form of pharmaceutically acceptable acid addition salt thereof.
2. A compound according to claim 1, wherein Ar is 5-dimethylamino-1-naphthyl
Figure imgb0022
is a piperidyl residue.
3. A compound according to claims 1 or 2 in hydrochloride form.
4. A compound according to one of the claims 1-3 in racemate form.
5. A compound according to one of the claims 1-3 in form of its optical antipodes.
6. A compound according to one of the claims 1-3 and 5 in substantially pure L-form.
7. Diagnostic preparation for determination of thrombin in blood containing one or more compounds according to one of the claims 186.
8. Pharmaceutical composition for treatment or prevention of thrombosis containing one or more compounds according to any of the claims 1-6.
9. Composition containing at least one compound according to claim 1 for use in a diagnostic method for determination of thrombin in blood.
10. A compound according to claims 1-6 for use in the treatment of thrombosis.
11. A process for the preparation of Na-arylsulfonyl-p-guanidinophenylalanine amides of the formula
Figure imgb0023
 wherein Ar is ortho-, meta- or para-tolyl, naphthyl-1, naphthyl-2 or 5-dimethylamino-1-naphthyl; R1 and R2 are an alkyl group having 1-5 carbon atoms or
Figure imgb0024
wherein n=2 or 3 and X is a single bond, CH2, CH-CH3, CH―C2H5, CH-C3H7, 0, NH or N-CH3, in free base form or in form of pharmaceutically acceptable acid addition salts thereof by
A. reacting a compound of the formula
Figure imgb0025
wherein R, and R2 are as defined previously, and a compound of the formula
Figure imgb0026
wherein Y is a reactive group, e.g. halogen which together with H2N can form a sulfonamide group, and wherein Ar is as defined previously,
B. by removal of the N02-group, e.g. by hydrogenation in a compound of the formula
Figure imgb0027
wherein R,, R2 and Ar are as defined previously.
12. A process according to claim 11 for preparation of a compound, wherein Ar is 5-dimethylamino-1-naphthyl and
Figure imgb0028
is a piperidyl residue.
EP83850149A 1982-06-23 1983-06-02 New thrombin inhibiting compounds Expired EP0097630B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT83850149T ATE22882T1 (en) 1982-06-23 1983-06-02 N-ALPHA-ARYLSULFONYL-P-GUANIDINOPHENYLALANINE DERIVATIVES AND PHARMACEUTICALS WITH THROMBINE INHIBITOR ACTIVITIES.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8203887 1982-06-23
SE8203887A SE8203887D0 (en) 1982-06-23 1982-06-23 NEW TROMBIN INHIBITIVE ASSOCIATIONS

Publications (3)

Publication Number Publication Date
EP0097630A2 EP0097630A2 (en) 1984-01-04
EP0097630A3 EP0097630A3 (en) 1984-07-04
EP0097630B1 true EP0097630B1 (en) 1986-10-15

Family

ID=20347156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83850149A Expired EP0097630B1 (en) 1982-06-23 1983-06-02 New thrombin inhibiting compounds

Country Status (6)

Country Link
US (1) US4537896A (en)
EP (1) EP0097630B1 (en)
JP (1) JPS5931757A (en)
AT (1) ATE22882T1 (en)
DE (1) DE3366917D1 (en)
SE (1) SE8203887D0 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62245932A (en) * 1986-04-18 1987-10-27 Haamo Sogo Kenkyusho:Kk Photodetector
US5200322A (en) * 1986-09-19 1993-04-06 Nippon Zoki Pharmaceutical Co., Ltd. Method for assaying protein C and measuring kit for the same
CA2005741C (en) * 1988-12-26 1998-06-02 Hiroyoshi Hidaka Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity
US5245034A (en) * 1988-12-26 1993-09-14 Kiroyoshi Hidaka Compound having vessel smooth muscle relaxation activity
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5256812A (en) * 1989-01-31 1993-10-26 Hoffmann-La Roche Inc. Carboxamides and sulfonamides
ZA92970B (en) * 1991-02-12 1992-10-28 Hoechst Ag Arylsulfonylureas,processes for their preparation,and their use as herbicides and growth regulators
DE4115468A1 (en) * 1991-05-11 1992-11-12 Behringwerke Ag AMIDINOPHENYLALANINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THE USE THESE AND THE MEANS THEREOF CONTAINING ANTICOAGULANTS
WO1993005014A1 (en) * 1991-09-05 1993-03-18 Pharno-Wedropharm Gmbh Aromatic sulfonamide derivatives, their use as enzyme inhibitors and pharmaceutical compositions containing them
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
US5227490A (en) * 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
TW223629B (en) * 1992-03-06 1994-05-11 Hoffmann La Roche
FR2689130B1 (en) * 1992-03-30 1994-05-27 Synthelabo DERIVATIVES OF 1- [2 (ARYLSULFONYLAMINO) ETHYL-1-OXO] PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
DE4225853A1 (en) * 1992-08-05 1994-02-10 Behringwerke Ag Granulocyte-binding antibody fragments, their production and use
DE4242655A1 (en) * 1992-12-17 1994-06-23 Behringwerke Ag Use of thrombin inhibitors to inhibit ocular fibrin formation
US5248673A (en) * 1992-12-23 1993-09-28 Bristol-Myers Squibb Co. Bisamidine derivatives as thrombin inhibitors
ATE223392T1 (en) * 1993-02-10 2002-09-15 Pentapharm Ag PIPERAZIDES OF SUBSTITUTED PHENYLALANINE DERIVATIVES AS THROMBIN INHIBITORS
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
FR2710067B1 (en) * 1993-09-14 1995-10-20 Synthelabo Process for the preparation of 2-amino-5- (1H-imidazol-4-yl) -1-oxopentylpiperidine.
WO1996005189A1 (en) * 1994-08-09 1996-02-22 Pentapharm Ag Inhibitors of the benzamidine type
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
AU2629795A (en) * 1994-12-12 1996-07-03 Chugai Seiyaku Kabushiki Kaisha Aniline derivative having the effect of inhibiting nitrogen monoxide synthase
KR0173034B1 (en) * 1995-04-28 1999-03-30 성재갑 Selective thrombin inhibitor
US5612378A (en) * 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
WO1997028128A1 (en) 1996-02-02 1997-08-07 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
GB9602294D0 (en) * 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
PL331599A1 (en) * 1996-08-14 1999-08-02 Zeneca Ltd Substituted derivatives of pyrimidine and their pharmaceutical application
UA56197C2 (en) 1996-11-08 2003-05-15 Зенека Лімітед Heterocyclic derivatives
AU5999698A (en) 1997-02-13 1998-09-08 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
ATE242774T1 (en) 1997-02-13 2003-06-15 Astrazeneca Ab HETEROCYCLIC COMPOUNDS THAT ARE USED AS OXIDOSQUALENE CYCLASE INHIBITORS
KR19980076024A (en) * 1997-04-04 1998-11-16 성재갑 Selective thrombin inhibitors for oral administration
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
ES2217879T3 (en) * 1998-12-24 2004-11-01 Eli Lilly And Company HETEROCICLIC AMIDAS.
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
DE10005631A1 (en) * 2000-02-09 2001-08-23 Max Planck Gesellschaft Arginine Mimetics as Factor X¶a¶ Inhibitors
WO2005033068A1 (en) * 2003-10-06 2005-04-14 Oy Juvantia Pharma Ltd Somatostatin receptor 1 and/or 4 selective agonists and antagonists
CN117143179B (en) * 2023-09-18 2024-07-12 安徽峆一药业股份有限公司 Synthesis method of thrombin chromogenic substrate S-2238

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE380257B (en) * 1972-05-02 1975-11-03 Bofors Ab NEW DIAGNOSTIC OPERATING SUBSTRATES WITH HIGH SPECIFICITY FOR THROMBIN AND OTHER PROTEOLYTIC ENZYMES OF THE PEPTIDYL-PEPTIDE HYDROLASES
US3978045A (en) * 1973-08-13 1976-08-31 Mitsubishi Chemical Industries Ltd. N2 -dansyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4069323A (en) * 1974-11-08 1978-01-17 Mitsubishi Chemical Industries Ltd. N2 -substituted-L-arginine derivatives and the pharmaceutically acceptable acid addition salts thereof
NL7512637A (en) * 1974-11-08 1976-05-11 Mitsubishi Chem Ind PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT, THE MEDICINAL PRODUCT CONTAINED THEREFORE AND PROCESS FOR THE PREPARATION OF THE ACTIVE COMPONENT.
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
NZ182812A (en) * 1975-12-09 1984-08-24 Mitsubishi Chem Ind N2-aryl(or aralkyl)sulphonyl-l-argininamides and pharmaceutical compositions
US4089957A (en) * 1976-06-11 1978-05-16 Ab Kabi Therapeutic compositions against recurrent thrombosis

Also Published As

Publication number Publication date
SE8203887D0 (en) 1982-06-23
EP0097630A3 (en) 1984-07-04
DE3366917D1 (en) 1986-11-20
ATE22882T1 (en) 1986-11-15
EP0097630A2 (en) 1984-01-04
JPS5931757A (en) 1984-02-20
US4537896A (en) 1985-08-27

Similar Documents

Publication Publication Date Title
EP0097630B1 (en) New thrombin inhibiting compounds
US5380713A (en) Peptide aldehydes as antithrombotic agents
CA1133897A (en) Peptidylarginine aldehyde derivatives and process for the preparation thereof
US5288707A (en) Borolysine peptidomimetics
US5153176A (en) Tripeptide derivatives and protease inhibitor composition comprising the same
US6492402B1 (en) Thrombin inhibitors
US6034067A (en) Serine protease inhibitors
IE921491A1 (en) Amidinophenylalanine derivatives, a process for the preparation thereof, use thereof and agents containing these as anticoagulants
RU2178419C2 (en) Serine protease inhibitors
AU650526B2 (en) Amidinophenylalanine derivatives, process for their preparation, their use and compositions containing them
WO1996021740A1 (en) Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods
EP0841918B1 (en) Thrombin inhibitors
US3821188A (en) Proline and pyroglutamic acid containing tripeptides
EP0313969B1 (en) Tripeptide derivatives and antiplasmin agents containing the same
US5328932A (en) Bisamidine derivatives as thrombin inhibitors
US4797472A (en) New peptide derivatives
KR20000064486A (en) N-acetyl (L) -4-cyanophenylalanine AC- (L) -PHE (4-CN) -OH and N-acetyl- (L) -P-amidinophenylalanine-cyclohexylglycine-B- (3 New preparation of -N-methylpyridinium) -alanine AC- (L) -CHG--PALNE (3) -NH2
US6774110B2 (en) Orally available peptidic thrombin inhibitors
DK171845B1 (en) Tripeptide derivatives and a process for preparing them, and a process for determining serine proteases or components which can co-operate with serine proteases
JP2560058B2 (en) New peptide derivatives
MXPA94006048A (en) L-valilamides and l-homovalilamides of 7alpha-amine-1, 1-dioxo-3-cephem.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RHK1 Main classification (correction)

Ipc: C07C143/78

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19841116

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 22882

Country of ref document: AT

Date of ref document: 19861115

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3366917

Country of ref document: DE

Date of ref document: 19861120

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19930521

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19930609

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19930614

Year of fee payment: 11

Ref country code: CH

Payment date: 19930614

Year of fee payment: 11

Ref country code: AT

Payment date: 19930614

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19930623

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19930630

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19930709

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19930719

Year of fee payment: 11

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19940602

Ref country code: GB

Effective date: 19940602

Ref country code: AT

Effective date: 19940602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19940603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19940630

Ref country code: CH

Effective date: 19940630

Ref country code: BE

Effective date: 19940630

BERE Be: lapsed

Owner name: KABI PHARMACIA A.B.

Effective date: 19940630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19950101

EUG Se: european patent has lapsed

Ref document number: 83850149.2

Effective date: 19950110

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19940602

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19950228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19950301

EUG Se: european patent has lapsed

Ref document number: 83850149.2

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST